Personalized mRNA vaccine for melanoma achieved positive results in phase three trial
Summary
Moderna and Merck announced that their experimental personalized mRNA vaccine, combined with the immunotherapy Keytruda, achieved positive results in the first phase three trial on over 1,100 patients with high-risk or advanced melanoma whose tumors were surgically removed. The combined therapy significantly extended the disease-free period and reduced the risk of cancer spreading to distant sites.
This summary was written by a language model from the 7 sources listed below.
Extract from the source
Eksperimentalno personalizirano cjepivo protiv raka koje razvijaju američke kompanije Moderna i Merck pokazalo je obećavajuće rezultate u velikom kliničkom ispitivanju, što otvara mogućnost njegove buduće
Locations
Only the locations this event's sources named.
Total — band napeto (40–69)
Sources (7)
- 02:40 PMVečernji list BiHOpen the original ↗
- 02:50 PMN1 BiHOpen the original ↗
- 03:02 PMOslobođenjeOpen the original ↗
- 03:37 PMAnadolija (Anadolu Agency, BS)Open the original ↗
- 03:40 PMDnevni avazOpen the original ↗
- 05:08 PMIndex.hrOpen the original ↗
- 09:30 PMBUKA (6yka)Open the original ↗
A headline and an extract of at most 25 words. The full text is never published; every source is named and linked.